First-in-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors | Zendy

Blair H. Smith | Zendy; Tapan Parikh | Zendy; Zoe P. Andrada | Zendy; Thomas J. Fahey | Zendy; Nathaniel Berman | Zendy; Madeline wiles | Zendy; Angelica Nazarian | Zendy; Joanne Thomas | Zendy; Anna Arreglado | Zendy; Eugene Akahoho | Zendy; David J. Wolf | Zendy; Daniel M. Levine | Zendy; Thomas S. Parker | Zendy; Lawrence S. Gazda | Zendy; Allyson J. Ocean | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

First-in-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors

Author(s) -

Blair H. Smith,

Tapan Parikh,

Zoe P. Andrada,

Thomas J. Fahey,

Nathaniel Berman,

Madeline wiles,

Angelica Nazarian,

Joanne Thomas,

Anna Arreglado,

Eugene Akahoho,

David J. Wolf,

Daniel M. Levine,

Thomas S. Parker,

Lawrence S. Gazda,

Allyson J. Ocean

Publication year - 2016

Publication title -

cancer growth and metastasis

Language(s) - English

Resource type - Journals

ISSN - 1179-0644

DOI - 10.4137/cgm.s39442

Subject(s) - medicine , malignancy , adverse effect , implant , urology , clinical trial , oncology , adenocarcinoma , cancer , surgery

Agarose macrobeads containing mouse renal adenocarcinoma cells (RMBs) release factors, suppressing the growth of cancer cells and prolonging survival in spontaneous or induced tumor animals, mediated, in part, by increased levels of myocyte-enhancing factor (MEF2D) via EGFR-and AKT-signaling pathways. The primary objective of this study was to determine the safety of RMBs in advanced, treatment-resistant metastatic cancers, and then its efficacy (survival), which is the secondary objective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research